Cochrane · systematic review · CD012656
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax
Milligan, R, Daher, A, Villanueva, G, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 4 · 28.6%Very low 6 · 42.9%Low 3 · 21.4%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings table 1 (main comparison)
Population: adults and children with confirmed clinical and parasitological P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence of P vivax parasitaemia | RR 0.96 [0.66, 1.39] | 4 studies · 1211 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events | no estimate extracted | 5 studies · 1427 participants | Ungraded |
Adverse events that result in the discontinuation of treatment | RR 1.04 [0.15, 7.38] | 5 studies · 1427 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Anaemia or change in haemoglobin status | RR 3 [0.12, 72.91] | 1 study · 240 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Summary of findings table 2
Population: adults and children with confirmed clinical and parasitological P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence of P vivax parasitaemia | RR 0.84 [0.49, 1.43] | 2 studies · 677 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events | no estimate extracted | 1 study · 778 participants | Ungraded |
Adverse events that result in the discontinuation of treatment | RR 4.19 [0.9, 19.6] | 1 study · 778 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Summary of findings table 3
Population: adults and children with confirmed clinical and parasitological P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence of P vivax malaria | RR 3.18 [0.37, 27.6] | 1 study · 122 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events | no estimate extracted | 1 study · 129 participants | Ungraded |
Anaemia (haemoglobin < 7 g/dL) | no estimate extracted | 1 study · 129 participants | Ungraded |
Summary of findings table 4
Population: adults and children with confirmed clinical and parasitological P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence of P vivax parasitaemia | RR 1.03 [0.82, 1.3] | 2 studies · 2526 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events | RR 12.03 [1.57, 92.3] | 1 study · 1872 participants | Low Downgraded: risk of bias, imprecision |
Adverse events the resulted in discontinuation of treatment | RR 2.5 [0.49, 12.87] | 2 studies · 2526 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Anaemia | RR 0.93 [0.62, 1.41] | 2 studies · 2440 participants | Very low Downgraded: risk of bias, imprecision, indirectness |